G-1 (CAS 881639-98-1): A Selective GPR30 Agonist for Rapid Estrogen Signaling

Executive Summary: G-1 (CAS 881639-98-1) acts as a highly selective agonist for GPR30/GPER1, displaying a binding affinity (Ki) of approximately 11 nM and negligible activity at classical nuclear estrogen receptors even at micromolar concentrations (Prossnitz 2008, DOI). G-1 triggers rapid intracellular signaling events, including calcium mobilization (EC50 = 2 nM) and PI3K-dependent PIP3 accumulation, distinguishing it from ERα and ERβ agonists (Bologa 2006, DOI). In vivo, G-1 demonstrates cardioprotective effects in heart failure models by attenuating cardiac fibrosis and modulating adrenergic receptor profiles (Wang 2021, DOI). G-1 effectively inhibits breast cancer cell migration with sub-nanomolar IC50 values in SKBr3 and MCF7 cells (Ariazi 2010, DOI). As a crystalline solid with robust solubility in DMSO and poor solubility in water or ethanol, G-1 is formulated for reproducible application in cell-based and animal models (see product details at APExBIO).

Biological Rationale

Estrogen signaling is mediated through both classical nuclear receptors (ERα, ERβ) and membrane-associated G protein-coupled receptors such as GPR30 (GPER1) (Wang 2021). GPR30 is localized primarily within the endoplasmic reticulum and plasma membrane and facilitates rapid, non-genomic estrogen responses, including modulation of intracellular calcium and kinase signaling cascades (Bologa 2006). Non-classical estrogen signaling is implicated in cardiovascular protection, immune regulation, and inhibition of tumor cell migration (internal review). G-1, a synthetic small molecule, was developed to selectively activate GPR30 without significant interaction with ERα or ERβ, enabling researchers to dissect the biological consequences of GPR30-specific signaling (APExBIO).

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds GPR30/GPER1 with a Ki of ~11 nM, inducing a conformational change that activates downstream G protein-coupled signaling pathways (Bologa 2006). Upon receptor activation, G-1 triggers:

• Elevation of intracellular Ca²⁺ levels (EC50 = 2 nM, measured in SKBr3 cells at 37°C in HBSS buffer) (Bologa 2006).
• PI3K activation and nuclear accumulation of PIP3, a pathway associated with cell survival and proliferation (Bologa 2006).
• Rapid, non-genomic signaling events distinct from those mediated by ERα and ERβ agonists such as PPT or DPN (Wang 2021).

These mechanisms enable G-1 to modulate cell migration, immune cell function, and tissue remodeling in both in vitro and in vivo systems.

Evidence & Benchmarks

• G-1 binds GPR30 with a Ki of ~11 nM and does not significantly bind ERα or ERβ at concentrations up to 10 µM (Bologa 2006).
• Induces a rapid increase in intracellular Ca²⁺ (EC50 = 2 nM) in GPR30-expressing breast cancer cells at 37°C (Bologa 2006).
• Inhibits migration of SKBr3 and MCF7 breast cancer cells with IC50 values of 0.7 nM and 1.6 nM, respectively (Ariazi 2010).
• Chronic administration in ovariectomized female Sprague-Dawley rats with heart failure reduces brain natriuretic peptide, inhibits cardiac fibrosis, and improves contractility via β-adrenergic receptor modulation (Wang 2021).
• G-1, but not ERβ agonist DPN, normalizes splenic CD4⁺ T lymphocyte proliferation post-hemorrhagic shock; effects are abolished by GPR30 antagonism (Wang 2021).

For a detailed guide on cell assay optimization with G-1, see this article, which this dossier extends by providing updated in vivo and mechanistic benchmarks.

Applications, Limits & Misconceptions

G-1 is widely applied to:

• Dissect rapid estrogen signaling mechanisms by separating GPR30 activity from canonical ERα/ERβ pathways.
• Investigate the inhibition of cell migration and proliferation in breast cancer models (Ariazi 2010).
• Study cardioprotective and anti-fibrotic effects in preclinical heart failure models (Wang 2021).
• Explore immunomodulation, particularly in the context of trauma and hemorrhagic shock (Wang 2021).

This article updates and clarifies strategic translational guidance provided in this internal review by offering peer-reviewed evidence for immunological models and direct workflow recommendations.

Common Pitfalls or Misconceptions

• G-1 is not an agonist for classical nuclear estrogen receptors (ERα or ERβ) and cannot be used to study their genomic signaling directly (Bologa 2006).
• It is insoluble in water or ethanol; improper solvent use may lead to precipitation and variable dosing (APExBIO).
• Long-term storage of G-1 solutions is not recommended due to potential degradation; stock solutions should be freshly prepared and stored at -20°C (APExBIO).
• Off-target effects may occur at concentrations orders of magnitude above the Ki; experimental controls are essential (Bologa 2006).
• Not all observed biological effects in estrogen signaling models are mediated by GPR30, and use of selective antagonists (e.g., G15) is required for mechanistic clarity (Wang 2021).

For further workflow-specific caveats and troubleshooting, see this resource, which this article extends with expanded mechanistic and in vivo data.

Workflow Integration & Parameters

G-1 is supplied as a crystalline solid (C₂₁H₁₈BrNO₃, MW 412.28; APExBIO SKU: B5455) and should be dissolved in DMSO to prepare stock solutions ≥10 mM. Warming and ultrasonic bath enhance dissolution. For cell culture, G-1 is typically diluted to working concentrations in complete growth media, ensuring final DMSO does not exceed 0.1% to avoid cytotoxicity. For animal models, dosing regimens must be optimized for species, route, and study duration. G-1 is insoluble in water and ethanol; use of alternative solvents leads to unreliable delivery (APExBIO).

Solutions should be aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles. Not recommended for extended long-term storage due to potential degradation of activity. For further optimization advice, see the APExBIO product page for G-1 (CAS 881639-98-1), a selective GPR30 agonist.

Conclusion & Outlook

G-1 (CAS 881639-98-1) is a validated and widely adopted research tool for dissecting GPR30-mediated rapid estrogen signaling in cardiovascular, cancer, and immunological models. Its high selectivity and potency, combined with robust in vitro and in vivo benchmarks, make it indispensable for studies requiring precise separation of GPR30 from classical estrogen receptor activity. Ongoing research continues to expand the applications of G-1 in translational and mechanistic studies. For authoritative sourcing and technical support, APExBIO provides comprehensive product documentation and workflow guidance.